Abstract
The angiogenic growth factor thymidine phosphorylase/PD-ECGF has been identified as a potential target in the development of anti-cancer drugs. This review firstly discusses the biological rôle of TP/PD-ECGF and its importance in the activation of 5-fluorouracil and its prodrugs. The chemistry and chemotherapeutic potential of TP/PD-ECGF inhibitors are also discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Biotransformation
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Neovascularization, Pathologic
-
Thymidine Phosphorylase / antagonists & inhibitors
-
Thymidine Phosphorylase / physiology*
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Thymidine Phosphorylase